Apellis shares have soared 45% since July 31 on narrower-than-expected Q2 losses and FDA approvals, closing Friday at a six-month high of $27.75. Revenue hit $178.5 million, led by Syfovre sales, while cash reserves reached $370 million. Yet short interest rose to 21.1%, signalling profit-taking bets. Analysts hiked targets, but retail sentiment stayed bearish with low activity.